Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16489034 | 0.86 | SCN10A (0.36) | ATRSCN10ASCN2A | |
| SCHEMBL16489020 | 0.84 | ATR (0.35) | ATRSCN10ASCN2A | |
| SCHEMBL13138295 | 0.83 | ATR (0.52) | ATR | |
| SCHEMBL16489041 | 0.79 | ATR (0.34) | ATRSCN10ASCN2A | |
| SCHEMBL18177406 | 0.79 | SCN2A (0.38) | ATRSCN10ASCN2A | |
| SCHEMBL16489025 | 0.78 | ATR (0.42) | ATRSCN10ASCN2A | |
| SCHEMBL18177386 | 0.77 | ATR (0.41) | ATRSCN10ASCN2A | |
| SCHEMBL18177404 | 0.76 | ATR (0.41) | ATRSCN10ASCN2A | |
| SCHEMBL16420710 | 0.76 | ATR (0.42) | ATR | |
| SCHEMBL16489022 | 0.76 | ATR (0.40) | ATRSCN10ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701674-B2 | Substituted pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-11 | — | — | US | disclosed |
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885SCN10A 4295/4885SCN2A 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.